Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a report issued on Wednesday, Marketbeat reports. The firm issued an overweight rating and a $12.00 price objective on the stock.

CMPX has been the subject of several other research reports. D. Boral Capital reissued a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partnrs lowered Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th. Leerink Partners lowered Compass Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Finally, Jefferies Financial Group raised their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $11.29.

Compass Therapeutics Price Performance

NASDAQ:CMPX traded down $0.16 during trading hours on Wednesday, hitting $2.92. The company had a trading volume of 1,126,664 shares, compared to its average volume of 1,313,643. The company has a market capitalization of $401.76 million, a PE ratio of -7.89 and a beta of 1.17. The stock has a 50-day moving average price of $2.43 and a 200 day moving average price of $1.88. Compass Therapeutics has a 52 week low of $0.76 and a 52 week high of $4.08.

Hedge Funds Weigh In On Compass Therapeutics

Several large investors have recently modified their holdings of CMPX. Enavate Sciences GP LLC purchased a new position in shares of Compass Therapeutics in the 4th quarter worth about $11,293,000. Tang Capital Management LLC raised its position in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the last quarter. MPM Bioimpact LLC raised its position in Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after buying an additional 2,926,002 shares during the last quarter. SG Americas Securities LLC raised its position in Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after buying an additional 356,352 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Compass Therapeutics by 512.5% in the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after buying an additional 227,864 shares during the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.